Navigation Links
Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
Date:11/20/2008

till over 40,000 deaths per year due to the disease in the Unites States alone.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at

SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
2. Bionovos VG101 Shows Greater Efficacy Than Estrogen in the Treatment of Vaginal Dryness
3. Bionovos MF101 Shows Statistically Significant Improvement in Sleep Disturbance from Hot Flashes
4. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
5. Bionovo Elucidates Mechanism of Breast Cancer Control by Estrogen Receptor Beta
6. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
7. Bionovo Discovers New Estrogen Regulatory Elements for Breast Cancer and Osteoporosis Drugs
8. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
9. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
10. Lytix Presents LTX-109 Anti-Microbial Data at ICAAC
11. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014 CTI BioPharma Corp. (CTI) (NASDAQ ... its second quarter 2014 financial results on Monday, August ... markets. Following the announcement, members of the management team ... results and provide a general corporate update at 4:30 ... can be obtained as follows: Monday, August ...
(Date:7/25/2014)... 25, 2014  Corporate libraries are constantly being faced ... in technology and how to cope with flat or ... pharmaceutical and medical device industries are increasingly finding it ... services they provide. According to recent ... many forces of change that leading corporate libraries are ...
(Date:7/25/2014)...  Depomed, Inc. (NASDAQ: DEPO ) today ... 2014 financial results after the market closes on Wednesday, August ... beginning at 4:30 pm EDT, 1:30 pm PDT to discuss its ... dialing 877-317-6789 ( United States ) or ... via a live webcast on the investor relations section ...
Breaking Medicine Technology:CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2Forces of Change Reshaping Corporate Libraries & Information Services 2Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2
... N.C., March 4, 2011 The pressure for a ... greater with organizations across the pharmaceutical sector facing pipeline ... Facing an ever-changing launch landscape, product launch leaders ... new therapies through the labyrinth of regulatory and marketplace ...
... 2011 Cardica, Inc. (Nasdaq: CRDC ) ... stapling device developed by Cardica has received CE Mark ... marking process, Cardica has obtained a Full Quality Assurance ... this certification, after successful completion of development, Cardica can ...
Cached Medicine Technology:Pharmaceutical Launch Excellence Services Delivers Market Entry Road Map 2Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device 2Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device 3Cardica Receives European CE Mark for Initial Microcutter™ Surgical Cutting and Stapling Device 4
(Date:7/28/2014)... With California in a record draught ... that a fire blanket that is over ... development by SunSeeker Enterprises, Inc. The fire blanket—utilizing the ... the extreme heat of re-entry into the Earth's atmosphere—will ... , “Our firefighters routinely lay their very lives on ...
(Date:7/28/2014)... July 28, 2014 At some point in ... where they’re forced to contact the authorities. Distinguishing the ... than it initially seems. , Not every dangerous situation is ... stolen, a person get mugged, or a bank get held ... leading onlookers to be more passive than they otherwise should. ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Drorit Silverman, ... unveiled new plans to raise investment capital through her ... fitness concept in the United States. , According to ... of 24/7 fitness centers provide a great window of ... rapidly expanding space. In addition to this, Silverman looks ...
(Date:7/28/2014)... July 28, 2014 The report ... Applications (Food & Beverages, Cleaning Agents, Bio-Fuel, Animal ... to 2018” defines and segments the global industrial ... global value for industrial enzymes. It also identifies ... enzymes market with analysis of trends, opportunities, burning ...
(Date:7/28/2014)... School of Medicine (BUSM) report variants in a new ... Alzheimer,s disease (AD). The discovery of this novel genetic ... target PLXNA4 specifically. These findings appear in the ... frequent age-related dementia affecting 5.4 million Americans including 13 ... than 40 percent of people age 85 and older. ...
Breaking Medicine News(10 mins):Health News:Revolutionary Fire Blanket Offers Over 200 Percent More Fire Protection to Firefighters and Homes 2Health News:Take Action To Protect Your Fellow Citizens 2Health News:Take Action To Protect Your Fellow Citizens 3Health News:Pro Bodybuilder Drorit Silverman Confirms Plans to Raise Money for Investment in the Popular 24/7 Fitness Concept 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4Health News:Researchers identify potential biomarker for AD 2
... A recent study estimates that nearly 30,000 men will ... study offers hope for these patients: // The combination ... improves survival rates. ,AST inhibits the release of ... three years of AST with radiation therapy has been ...
... compression stockings can reduce complications after a blood clot ... uncomfortable .// ,Some of the common complications with ... leg include swelling, skin discoloration, numbness, chronic pain, hardening ... suggested that elastic stockings could help patients with blood ...
... of people worldwide . It is the most common form ... are still unknown and there is no cure. ,New ... to treating Alzheimer’s disease. A team of researchers tested ... were given sage oil capsules, and some were given placebos. ...
... to researchers a group of cells, called satellite cells, ... older people maintain // their youthfulness. These cells rescue ... They also generate new cells for future repairs. Previous ... protein called Notch is activated by another protein called ...
... Chronic obstructive pulmonary disease, an often neglected disease of the ... The vast majority of people with the disease are smokers. ... from wood fires also comes into play in some cases. ... in fact, it will be the third leading cause of ...
... news for the many adults and children who have endured ... ,Developing a vaccine to prevent group A streptococcal infections has ... years. Group A streptococcus is responsible for a variety of ... most common. ,The vaccine trial included 28 adults ...
Cached Medicine News:
The Advance Unicompartmental Knee System is designed with bone conserving femoral and tibial components that provide reproducible results within a minimal incision. Uni metal backed tibial component....
...
...
... Severe revision options for the knee and ... modular system for the knee and hip ... that include surgical indication, implant selection, connection ... individual needs. This system addresses the needs ...
Medicine Products: